Overview

An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)

Status:
Terminated

Trial end date:
2016-08-01

Target enrollment:

Participant gender:

Summary

The study hypothesis is that lenalidomide and romidepsin (and dexamethasone for patients with myeloma) will have an acceptable toxicity profile and that in combination will have sufficient activity in the target population (including those previously refractory to HDACi monotherapy) to warrant further investigation.

Phase:

Phase 1

Details

Lead Sponsor:

Yale University

Collaborator:

Peter MacCallum Cancer Centre, Australia

Treatments:

Lenalidomide
Romidepsin
Thalidomide